Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics

Anixa Biosciences, Inc. (ANIX): $3.16

-0.06 (-1.86%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add ANIX to Watchlist
Sign Up

ANIX Price/Volume Stats

Current price $3.16 52-week high $6.45
Prev. close $3.22 52-week low $2.77
Day low $3.00 Volume 89,000
Day high $3.34 Avg. volume 78,763
50-day MA $4.18 Dividend yield N/A
200-day MA $4.51 Market Cap 97.72M

ANIX Stock Price Chart Interactive Chart >


Anixa Biosciences, Inc. (ANIX) Company Bio


Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.


ANIX Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIX Latest Social Stream


Loading social stream, please wait...

View Full ANIX Social Stream

Latest ANIX News From Around the Web

Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Yahoo | May 22, 2023

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Yahoo | April 25, 2023

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Yahoo | April 18, 2023

Anixa Biosciences Clarifies Poster Presentation on Company Website

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that a technical error was made by the company's website hosting service provider, causing a poster presentation unrelated to Anixa to be posted on the Corporate Presentations page of the company's website. The correct presentation of the company's breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting may be found on the Events page of the company's w

Yahoo | April 17, 2023

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine. The data presented showed that in the vaccinated women who have been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. The presentation was made by G. Thomas Budd, M.D., of Cleveland Clinic's Taussig Cancer I

Yahoo | April 17, 2023

Read More 'ANIX' Stories Here

ANIX Price Returns

1-mo -21.00%
3-mo -32.33%
6-mo -35.38%
1-year -11.98%
3-year 38.60%
5-year -14.36%
YTD -25.65%
2022 43.10%
2021 -3.26%
2020 -6.40%
2019 -16.75%
2018 66.95%

Continue Researching ANIX

Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:

Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!